Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 25, Number 4—April 2019

Research

Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia

Hail M. Al-Abdely1, Claire M. Midgley1Comments to Author , Abdulrahim M. Alkhamis, Glen R. Abedi, Xiaoyan Lu, Alison M. Binder, Khalid H. Alanazi, Azaibi Tamin, Weam M. Banjar, Sandra Lester, Osman Abdalla, Rebecca M. Dahl, Mutaz Mohammed, Suvang Trivedi, Homoud S. Algarni, Senthilkumar K. Sakthivel, Abdullah Algwizani, Fahad Bafaqeeh, Abdullah Alzahrani, Ali Abraheem Alsharef, Raafat F. Alhakeem, Hani A. Aziz Jokhdar, Sameeh S. Ghazal, Natalie J. Thornburg, Dean D. Erdman, Abdullah M. Assiri, John T. WatsonComments to Author , and Susan I. Gerber
Author affiliations: Ministry of Health, Riyadh, Saudi Arabia (H.M. Al-Abdely, A.M. Alkhamis, K.H. Alanazi, W.M. Banjar, O. Abdalla, M. Mohammed, H.S. Algarni, A. Alzahrani, A.A. Alsharef, R.F. Alhakeem, H.A.A. Jokhdar, A.M. Assiri); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.M. Midgley, G.R. Abedi, X. Lu, A.M. Binder, A. Tamin, S. Lester, R.M. Dahl, S.K. Sakthivel, N.J. Thornburg, D.D. Erdman, J.T. Watson, S.I. Gerber); Princess Nourah Bint Abdulrahman University, Riyadh (W.M. Banjar); Prince Mohammed Bin Abdulaziz Hospital, Riyadh (A. Algwizani, F. Bafaqeeh, S.S. Ghazal)

Main Article

Table 4

Specimens and MERS–CoV patients with detectable Abs, by time since illness onset and outcome, Saudi Arabia, August 1, 2015–August 31, 2016*

Outcome Days since onset No. specimens with Abs detected/no. tested
 No. patients† with Abs detected/no. tested
MN VSV-MERS-S S ELISA N ELISA MN VSV-MERS-S S ELISA N ELISA
Survived <14 3/17 4/16 5/17 7/17 3/11 4/10 4/11 5/11
14–20 4/8 4/8 4/8 6/8 3/5 3/5 3/5 4/5
21–27 6/6 5/5 6/6 6/6 3/3 3/3 3/3 3/3
28–55 10/10 10/10 10/10 10/10 4/4 4/4 4/4 4/4
1 y
 4/4
 4/4
 4/4
 2/4
4/4
 4/4
 4/4
 2/4
Died <14 9/11 8/11 5/11 8/11 5/6 5/6 3/6 4/6
14–20 9/9 6/8 7/9 9/9 4/4 2/3 4/4 4/4
21–27 9/9 8/9 8/9 9/9 4/4 4/4 4/4 4/4
28–55 4/4 4/4 4/4 4/4 3/3 3/3 3/3 3/3
1 y NA NA NA NA NA NA NA NA

*Abs, antibodies; MERS-CoV, Middle East respiratory syndrome coronavirus; MN, microneutralization assay; N ELISA, nucleocapsid ELISA; S ELISA, spike ELISA; VSV-MERS-S, pseudoparticle neutralization assay; NA, not available.
†Number of patients represents those with available specimens for a given period. Specimens were not available from all patients during all periods. Some specimens were not tested by VSV-MERS-S pseudoparticle assay because of insufficient volume.

Main Article

1These first authors contributed equally to this article.

Page created: March 18, 2019
Page updated: March 18, 2019
Page reviewed: March 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external